Cellectar Biosciences, Inc. — Q1 2015 Form 10-Q
Business context and period. The company is a development-stage biopharmaceutical business focused on cancer treatment, diagnosis and imaging. This filing reports the three months ended March 31, 2015, with comparisons to Q1 2014. It reports no product revenue; operations are funded primarily through equity and debt financing.
Key financial results
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $1.644 million | $1.715 million; down 4% |
| General and administrative expense | $0.943 million | $1.087 million; down 13% |
| Total operating expenses / operating loss | $2.587 million | $2.819 million |
| Net loss | $2.301 million | $2.943 million |
| Basic and diluted loss per share | $0.30 | $1.03 |
| Cash used in operating activities | $2.366 million | $2.595 million |
| Capital expenditures | $25,466 | $15,191 |
No meaningful gross margin is reported because the company had no product revenue. The lower net loss reflected reduced operating expenses, a $288,251 gain from warrant revaluation versus a $54,945 loss in Q1 2014, and substantially lower interest expense after the convertible debentures were exchanged in August 2014. Weighted-average shares rose to 7.56 million from 2.87 million, affecting the year-over-year per-share comparison.
Balance sheet and liquidity
- At March 31, 2015, cash and cash equivalents were $7.030 million, down $2.393 million from December 31, 2014. Restricted cash was $55,000.
- Total current assets were $7.256 million and current liabilities were $5.896 million, an approximate 1.23 current ratio.
- Total liabilities were $6.323 million; stockholders’ equity was $4.588 million.
- Notes payable totaled $450,000, comprising $180,370 current and $269,630 long-term. Capital lease obligations totaled approximately $12,095.
- The $4.889 million derivative liability relates to warrants with cash-settlement or down-round provisions; it is not presented as conventional funded debt.
- Operating cash use was partly offset in the reconciliation by noncash items, including $191,790 of stock-based compensation and $90,044 of depreciation and amortization. The company received no financing proceeds in Q1 2015, compared with $4.0 million of convertible-debenture proceeds in Q1 2014.
Business developments, outlook and risks
- Pipeline: Investigator-sponsored Phase 1/2 studies of I-124-CLR1404 imaging were ongoing across 11 solid-tumor indications; management anticipated glioblastoma Phase 2 data during 2015. The first patient entered the I-131-CLR1404 multiple-myeloma proof-of-concept trial in April 2015. The company filed an IND for CLR1502 in February 2015.
- Funding outlook: Management expected continued operating losses and said additional financing would be needed. It stated that available cash would fund operations through the third quarter of 2015, while a risk-factor disclosure said cash was adequate into the fourth quarter. Management said it was pursuing financing alternatives but had not entered negotiations; there was no assurance of funding. The financial statements include a going-concern uncertainty.
- Controls: Management reported a material weakness in internal control over financial reporting concerning classification of the August 2014 warrants, and concluded disclosure controls were not effective. Management stated the financial statements were fairly stated and described remediation efforts, while cautioning that success was not assured.
- Other risks and items: Clinical and regulatory development, ability to raise capital, potential dilution or surrender of product rights, and the possibility of delaying or ending programs are material risks. Management said ordinary-course legal matters were not expected to materially affect the financial statements. The company was invoiced $285,185 by the University of Wisconsin for clinical-trial costs during the quarter, of which $262,968 had been paid; the university relationship involves a director and shareholder who is also the company’s chief scientific officer.
Most important facts to verify
- Reconcile management’s different cash-runway statements (through Q3 versus into Q4) and the differing cash figures in the filing: $7.030 million in the financial statements/MD&A versus $7.085 million in a risk-factor disclosure.
- Reconcile the MD&A’s statement that Q1 2015 net loss was approximately $2.501 million with the financial statements’ reported net loss of $2.301 million.
- Track financing progress and cash burn given the stated limited runway, ongoing losses and going-concern uncertainty.
- Assess remediation of the material weakness and the accounting and potential dilution implications of outstanding warrants, including 6.60 million warrants and a $4.889 million derivative liability.
- Verify the timing and results of clinical milestones, including the anticipated glioblastoma imaging data and the newly initiated multiple-myeloma trial.